Albendazole versus metronidazole in the treatment of patients with giardiasis in the Islamic Republic of Iran

East Mediterr Health J. 2006 Sep;12(5):548-54.

Abstract

We examined the therapeutic effects of albendazole compared to metronidazole in 120 patients with giardiasis in Hamdan. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days). Demographic data of the patients, results of stool examination for Giardia trophozoites before and after treatment, and drug side-effects were recorded. After treatment 6 (10.0%) of the albendazole group had trophozoites compared with 14 (23.3%) of metronidazole group (P < 0.05). Patients in the albendazole group had fewer side-effects while 43.3% of the metronidazole group experienced a metallic taste and 35.0% experienced loss of appetite. Albendazole is an easy, safe and effective treatment for giardiasis.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Albendazole / adverse effects
  • Albendazole / therapeutic use*
  • Anorexia / chemically induced
  • Antiprotozoal Agents / adverse effects
  • Antiprotozoal Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Feces / parasitology
  • Female
  • Follow-Up Studies
  • Giardiasis / drug therapy*
  • Giardiasis / parasitology
  • Humans
  • Iran
  • Male
  • Metronidazole / adverse effects
  • Metronidazole / therapeutic use*
  • Middle Aged
  • Safety
  • Single-Blind Method
  • Taste Disorders / chemically induced
  • Treatment Outcome
  • Urban Health

Substances

  • Antiprotozoal Agents
  • Metronidazole
  • Albendazole